I agree that this site is using cookies. You can find further informations here.
X
Pratz, Keith W.
121  results:
Search for persons X
?
1

Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine ..:

Pratz, Keith W. ; Jonas, Brian A. ; Pullarkat, Vinod...
American Journal of Hematology.  99 (2024)  4 - p. 615-624 , 2024
Link: https://doi.org/10.1002/..
 
?
2

Preconditioning Frailty Phenotype Influences Survival and R..:

Sung, Anthony D. ; Koll, Thuy ; Gier, Shannon H....
Transplantation and Cellular Therapy.  30 (2024)  4 - p. 415.e1-415.e16 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Post-Transplant Frailty Phenotype Predicts Survival:

Hadjis, Ashley D. ; White, Griffin W. ; Gill, Saar I....
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S407-S408 , 2024
Link: https://doi.org/10.1016/..
 
?
4

Hypomethylating agents are associated with high rates of he..:

Connor, Matthew P. ; Prathapa, Neeharika ; Frey, Noelle V....
Haematologica.  , 2024
Link: https://doi.org/10.3324/..
 
?
5

Recent advances in targeted therapies in acute myeloid leuk..:

Bhansali, Rahul S. ; Pratz, Keith W. ; Lai, Catherine
Journal of Hematology & Oncology.  16 (2023)  1 - p. , 2023
Link: https://doi.org/10.1186/..
 
?
6

Real‐world effectiveness of intensive chemotherapy with 7&3..:

Matthews, Andrew H. ; Perl, Alexander E. ; Luger, Selina M....
American Journal of Hematology.  98 (2023)  8 - p. 1254-1264 , 2023
Link: https://doi.org/10.1002/..
 
?
7

Clofarabine and Busulfan Myeloablative Conditioning in Allo..:

Connor, Matthew P. ; Loren, Alison W. ; Hexner, Elizabeth O....
Transplantation and Cellular Therapy.  29 (2023)  2 - p. 113-118 , 2023
Link: https://doi.org/10.1016/..
 
?
8

Poster: AML-256 A Phase 1 Study of Gilteritinib in Combinat..:

Pratz, Keith W. ; Cherry, Mohamad ; Podoltsev, Nikolai A....
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S126 , 2022
Link: https://doi.org/10.1016/..
 
?
9

Venetoclax combinations delay the time to deterioration of ..:

Pratz, Keith W. ; Panayiotidis, Panayiotis ; Recher, Christian...
Blood Cancer Journal.  12 (2022)  4 - p. , 2022
Link: https://doi.org/10.1038/..
 
?
10

Impact of FLT3 Mutation on Outcomes after Venetoclax and Az..:

Konopleva, Marina ; Thirman, Michael J. ; Pratz, Keith W....
Clinical Cancer Research.  28 (2022)  13 - p. 2744-2752 , 2022
Link: https://doi.org/10.1158/..
 
?
11

Outcomes in Patients with Poor-Risk Cytogenetics with or wi..:

Pollyea, Daniel A. ; Pratz, Keith W. ; Wei, Andrew H....
Clinical Cancer Research.  28 (2022)  24 - p. 5272-5279 , 2022
Link: https://doi.org/10.1158/..
 
?
12

Postremission cytopenia management in patients with acute m..:

Pratz, Keith W. ; DiNardo, Courtney D. ; Selleslag, Dominik...
American Journal of Hematology.  97 (2022)  11 - p. , 2022
Link: https://doi.org/10.1002/..
 
?
13

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 ..:

Pratz, Keith W. ; Kaplan, Jason ; Levy, Moshe...
Haematologica.  , 2022
Link: https://doi.org/10.3324/..
 
?
14

Targeting Menin and CD47 to Address Unmet Needs in Acute My..:

Matthews, Andrew H. ; Pratz, Keith W. ; Carroll, Martin P.
Cancers.  14 (2022)  23 - p. 5906 , 2022
Link: https://doi.org/10.3390/..
 
?
15

Day 4 vs. day 12 G-CSF administration following reduced int..:

Hatch, Rachel V. ; Freyer, Craig W. ; Carulli, Alison...
Journal of Oncology Pharmacy Practice.  28 (2022)  4 - p. 892-897 , 2022
Link: https://doi.org/10.1177/..
 
1-15